Streetbeat News

Products Services

INSM

Insmed Incorporated (NASDAQ:INSM) provided a business update at the 42nd Annual J.P. Morgan Healthcare Conference, forecasting 2024 global ARIKAYCE revenues of $340M-$360M, exceeding FY23 guidance with unaudited sales of ~$305.2M. The company expects significant growth and transformative developments in 2024, including topline data from Phase 3 ASPEN study of Brensocatib and Phase 2 study of TPIP. Insmed's early-stage research comprises over 30 pre-clinical programs, with less than 20% of overall spend.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 1:06 pm

COYA

Coya Therapeutics announced successful pre-IND and Type C meetings with the FDA regarding the development of COYA 302, a treatment for Amyotrophic Lateral Sclerosis (ALS). These meetings are critical steps in advancing the drug towards clinical trials and potential approval.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 1:05 pm

AAPL

Clicks Technology is launching a physical keyboard accessory for Apple Inc.'s iPhones, named 'Clicks'. This $139 device connects via Lightning or USB-C and offers benefits such as freeing up screen space, improving typing accuracy and speed, and supporting iOS shortcuts. It is tailored for iPhone 14 Pro, iPhone 15 Pro, and iPhone 15 Pro Max, with pre-orders available and shipping starting on Feb. 1.

Portfolio Pulse from Ananya Gairola

January 05, 2024 | 12:43 pm

ELEV

Elevation Oncology announced that the update from its ongoing Phase 1 clinical trial of EO-3021 is now expected in mid-2024. The company also stated it is in a strong financial position, with sufficient cash to last into the second half of 2025.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 12:39 pm

BTTC

Bitech Technologies has announced receiving an initial purchase order for its innovative energy-saving Virtual Power Plant (VPP) solution, marking the company's entry into the Building Energy Management System (BEMS) market. This move represents a strategic expansion for Bitech Technologies, potentially opening up new revenue streams and partnerships in the energy management sector.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 12:33 pm

PRQR

ProQR Therapeutics has partnered with the Rett Syndrome Research Trust to use Axiomer RNA editing technology for developing therapies for central nervous system diseases. This collaboration aims to leverage ProQR's proprietary technology to address genetic mutations without altering the DNA, potentially offering new treatment avenues for patients with CNS diseases.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 12:15 pm

CVAC

GSK

CureVac has announced positive interim results from the Phase 2 study of its COVID-19 vaccine, developed in collaboration with GlaxoSmithKline (GSK). The results validate CureVac's proprietary technology platform, which could have implications for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 12:08 pm

GNPX

Genprex has announced that enrollment for its Acclaim-1 Phase 2A and Acclaim-3 Phase 1 clinical studies will open in January 2024. These studies are significant steps in the company's clinical development efforts.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 12:07 pm

TLSA

Tiziana Life Sciences announced the filing of a new patent application for a combination therapy that includes its proprietary Anti-CD3 (Foralumab) and a GLP-1 receptor agonist. This therapy aims to further reduce obesity-associated inflammation.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 12:05 pm

DCPH

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) announced that Nature Medicine published results from a ctDNA analysis of the INTRIGUE Phase 3 study of QINLOCK in GIST patients. The study focused on patients with mutations in KIT exon 11 and 17/18 who were previously treated with imatinib, showing substantial clinical benefit of QINLOCK.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 12:02 pm